Targeting galectin-1 impairs castration-resistant prostate cancer progression and invasion

Tsung Chieh Shih, Ruiwu Liu, Chun Te Wu, Xiaocen Li, Wenwu Xiao, Xiaojun Deng, Sophie Kiss, Ting Wang, Xiao Jia Chen, Randy Carney, Hsing-Jien Kung, Yong Duan, Paramita M Ghosh, Kit Lam

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: The majority of patients with prostate cancer who are treated with androgen-deprivation therapy (ADT) will eventually develop fatal metastatic castration-resistant prostate cancer (mCRPC). Currently, there are no effective durable therapies for patients with mCRPC. High expression of galectin-1 (Gal-1) is associated with prostate cancer progression and poor clinical outcome. The role of Gal-1 in tumor progression is largely unknown. Here, we characterized Gal-1 functions and evaluated the therapeutic effects of a newly developed Gal-1 inhibitor, LLS30, in mCRPC. Experimental Design: Cell viability, colony formation, migration, and invasion assays were performed to examine the effects of inhibition of Gal-1 in CRPC cells. We used two human CRPC xenograft models to assess growth-inhibitory effects of LLS30. Genome-wide gene expression analysis was conducted to elucidate the effects of LLS30 on metastatic PC3 cells. Results: Gal-1 was highly expressed in CRPC cells, but not in androgen-sensitive cells. Gal-1 knockdown significantly inhibited CRPC cells' growth, anchorage-independent growth, migration, and invasion through the suppression of androgen receptor (AR) and Akt signaling. LLS30 targets Gal-1 as an allosteric inhibitor and decreases Gal-1–binding affinity to its binding partners. LLS30 showed in vivo efficacy in both AR-positive and AR-negative xenograft models. LLS30 not only can potentiate the antitumor effect of docetaxel to cause complete regression of tumors, but can also effectively inhibit the invasion and metastasis of prostate cancer cells in vivo. Conclusions: Our study provides evidence that Gal-1 is an important target for mCRPC therapy, and LLS30 is a promising small-molecule compound that can potentially overcome mCRPC.

Original languageEnglish (US)
Pages (from-to)4319-4331
Number of pages13
JournalClinical Cancer Research
Volume24
Issue number17
DOIs
StatePublished - Sep 1 2018

Fingerprint

Galectin 1
Castration
Prostatic Neoplasms
Androgen Receptors
docetaxel
Heterografts
Androgens
Growth
Therapeutic Uses
Neoplasms
Cell Survival
Research Design
Therapeutics
Genome
Neoplasm Metastasis
Gene Expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting galectin-1 impairs castration-resistant prostate cancer progression and invasion. / Shih, Tsung Chieh; Liu, Ruiwu; Wu, Chun Te; Li, Xiaocen; Xiao, Wenwu; Deng, Xiaojun; Kiss, Sophie; Wang, Ting; Chen, Xiao Jia; Carney, Randy; Kung, Hsing-Jien; Duan, Yong; Ghosh, Paramita M; Lam, Kit.

In: Clinical Cancer Research, Vol. 24, No. 17, 01.09.2018, p. 4319-4331.

Research output: Contribution to journalArticle

Shih, Tsung Chieh ; Liu, Ruiwu ; Wu, Chun Te ; Li, Xiaocen ; Xiao, Wenwu ; Deng, Xiaojun ; Kiss, Sophie ; Wang, Ting ; Chen, Xiao Jia ; Carney, Randy ; Kung, Hsing-Jien ; Duan, Yong ; Ghosh, Paramita M ; Lam, Kit. / Targeting galectin-1 impairs castration-resistant prostate cancer progression and invasion. In: Clinical Cancer Research. 2018 ; Vol. 24, No. 17. pp. 4319-4331.
@article{21415ace5943432d940039cfcd0f1dfb,
title = "Targeting galectin-1 impairs castration-resistant prostate cancer progression and invasion",
abstract = "Purpose: The majority of patients with prostate cancer who are treated with androgen-deprivation therapy (ADT) will eventually develop fatal metastatic castration-resistant prostate cancer (mCRPC). Currently, there are no effective durable therapies for patients with mCRPC. High expression of galectin-1 (Gal-1) is associated with prostate cancer progression and poor clinical outcome. The role of Gal-1 in tumor progression is largely unknown. Here, we characterized Gal-1 functions and evaluated the therapeutic effects of a newly developed Gal-1 inhibitor, LLS30, in mCRPC. Experimental Design: Cell viability, colony formation, migration, and invasion assays were performed to examine the effects of inhibition of Gal-1 in CRPC cells. We used two human CRPC xenograft models to assess growth-inhibitory effects of LLS30. Genome-wide gene expression analysis was conducted to elucidate the effects of LLS30 on metastatic PC3 cells. Results: Gal-1 was highly expressed in CRPC cells, but not in androgen-sensitive cells. Gal-1 knockdown significantly inhibited CRPC cells' growth, anchorage-independent growth, migration, and invasion through the suppression of androgen receptor (AR) and Akt signaling. LLS30 targets Gal-1 as an allosteric inhibitor and decreases Gal-1–binding affinity to its binding partners. LLS30 showed in vivo efficacy in both AR-positive and AR-negative xenograft models. LLS30 not only can potentiate the antitumor effect of docetaxel to cause complete regression of tumors, but can also effectively inhibit the invasion and metastasis of prostate cancer cells in vivo. Conclusions: Our study provides evidence that Gal-1 is an important target for mCRPC therapy, and LLS30 is a promising small-molecule compound that can potentially overcome mCRPC.",
author = "Shih, {Tsung Chieh} and Ruiwu Liu and Wu, {Chun Te} and Xiaocen Li and Wenwu Xiao and Xiaojun Deng and Sophie Kiss and Ting Wang and Chen, {Xiao Jia} and Randy Carney and Hsing-Jien Kung and Yong Duan and Ghosh, {Paramita M} and Kit Lam",
year = "2018",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-18-0157",
language = "English (US)",
volume = "24",
pages = "4319--4331",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Targeting galectin-1 impairs castration-resistant prostate cancer progression and invasion

AU - Shih, Tsung Chieh

AU - Liu, Ruiwu

AU - Wu, Chun Te

AU - Li, Xiaocen

AU - Xiao, Wenwu

AU - Deng, Xiaojun

AU - Kiss, Sophie

AU - Wang, Ting

AU - Chen, Xiao Jia

AU - Carney, Randy

AU - Kung, Hsing-Jien

AU - Duan, Yong

AU - Ghosh, Paramita M

AU - Lam, Kit

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Purpose: The majority of patients with prostate cancer who are treated with androgen-deprivation therapy (ADT) will eventually develop fatal metastatic castration-resistant prostate cancer (mCRPC). Currently, there are no effective durable therapies for patients with mCRPC. High expression of galectin-1 (Gal-1) is associated with prostate cancer progression and poor clinical outcome. The role of Gal-1 in tumor progression is largely unknown. Here, we characterized Gal-1 functions and evaluated the therapeutic effects of a newly developed Gal-1 inhibitor, LLS30, in mCRPC. Experimental Design: Cell viability, colony formation, migration, and invasion assays were performed to examine the effects of inhibition of Gal-1 in CRPC cells. We used two human CRPC xenograft models to assess growth-inhibitory effects of LLS30. Genome-wide gene expression analysis was conducted to elucidate the effects of LLS30 on metastatic PC3 cells. Results: Gal-1 was highly expressed in CRPC cells, but not in androgen-sensitive cells. Gal-1 knockdown significantly inhibited CRPC cells' growth, anchorage-independent growth, migration, and invasion through the suppression of androgen receptor (AR) and Akt signaling. LLS30 targets Gal-1 as an allosteric inhibitor and decreases Gal-1–binding affinity to its binding partners. LLS30 showed in vivo efficacy in both AR-positive and AR-negative xenograft models. LLS30 not only can potentiate the antitumor effect of docetaxel to cause complete regression of tumors, but can also effectively inhibit the invasion and metastasis of prostate cancer cells in vivo. Conclusions: Our study provides evidence that Gal-1 is an important target for mCRPC therapy, and LLS30 is a promising small-molecule compound that can potentially overcome mCRPC.

AB - Purpose: The majority of patients with prostate cancer who are treated with androgen-deprivation therapy (ADT) will eventually develop fatal metastatic castration-resistant prostate cancer (mCRPC). Currently, there are no effective durable therapies for patients with mCRPC. High expression of galectin-1 (Gal-1) is associated with prostate cancer progression and poor clinical outcome. The role of Gal-1 in tumor progression is largely unknown. Here, we characterized Gal-1 functions and evaluated the therapeutic effects of a newly developed Gal-1 inhibitor, LLS30, in mCRPC. Experimental Design: Cell viability, colony formation, migration, and invasion assays were performed to examine the effects of inhibition of Gal-1 in CRPC cells. We used two human CRPC xenograft models to assess growth-inhibitory effects of LLS30. Genome-wide gene expression analysis was conducted to elucidate the effects of LLS30 on metastatic PC3 cells. Results: Gal-1 was highly expressed in CRPC cells, but not in androgen-sensitive cells. Gal-1 knockdown significantly inhibited CRPC cells' growth, anchorage-independent growth, migration, and invasion through the suppression of androgen receptor (AR) and Akt signaling. LLS30 targets Gal-1 as an allosteric inhibitor and decreases Gal-1–binding affinity to its binding partners. LLS30 showed in vivo efficacy in both AR-positive and AR-negative xenograft models. LLS30 not only can potentiate the antitumor effect of docetaxel to cause complete regression of tumors, but can also effectively inhibit the invasion and metastasis of prostate cancer cells in vivo. Conclusions: Our study provides evidence that Gal-1 is an important target for mCRPC therapy, and LLS30 is a promising small-molecule compound that can potentially overcome mCRPC.

UR - http://www.scopus.com/inward/record.url?scp=85052743253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052743253&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-0157

DO - 10.1158/1078-0432.CCR-18-0157

M3 - Article

C2 - 29666302

AN - SCOPUS:85052743253

VL - 24

SP - 4319

EP - 4331

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -